
CC-90003
CAS No. 1621999-82-3
CC-90003 ( CC90003 )
产品货号. M12390 CAS No. 1621999-82-3
CC-90003 (CC90003) 是一种有效的选择性共价 ERK1/2 抑制剂,IC50 为 10-20 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥575 | 有现货 |
![]() ![]() |
5MG | ¥818 | 有现货 |
![]() ![]() |
10MG | ¥1385 | 有现货 |
![]() ![]() |
25MG | ¥2730 | 有现货 |
![]() ![]() |
50MG | ¥3969 | 有现货 |
![]() ![]() |
100MG | ¥5897 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称CC-90003
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CC-90003 (CC90003) 是一种有效的选择性共价 ERK1/2 抑制剂,IC50 为 10-20 nM。
-
产品描述CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel; potently inhibits 27 growth of KRAS mutant cell lines with GI50 of <1 uM, also is active against 28 of 37 (76%) KRAS-mutant cancer cell lines, shows cytotoxic effects in KRAS mutant PDAC, lung cancer and CRC cell lines, does not significantly inhibit proliferation of normal lung fibroblasts or bronchial epithelial cells; decreases colony formation ex-vivo and inhibits tumor growth in vivo of KRAS mutant PDX models, induces full regression and prevents regrowth of KRAS mutant Lung PDX model when combined with Docetaxel.(In Vitro):CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
-
体外实验CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
-
体内实验——
-
同义词CC90003
-
通路MAPK/ERK Signaling
-
靶点ERK
-
受体ERK
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1621999-82-3
-
分子量458.445
-
分子式C22H21F3N6O2
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 125 mg/mL 272.66 mM; H2O : < 0.1 mg/mL
-
SMILESC=CC(NC1=CC(C)=CC=C1NC2=NC(NC3=CC(OC)=NC=C3C)=NC=C2C(F)(F)F)=O
-
化学全称N-(2-((2-((2-methoxy-5-methylpyridin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-5-methylphenyl)acrylamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Aronchik I, et al. Mol Cancer Res. 2018 Oct 1. pii: molcanres.0554.2017. doi: 10.1158/1541-7786.MCR-17-0554.